Magnus Medical

Magnus Medical this week announced the commercial launch of its Saint neuromodulation system for treatment-resistant major depressive disorder (MDD).

The Saint treatment changes a patient’s brain circuitry to treat MDD more effectively. It modifies activity in brain networks that are related to depression.

Saint won FDA breakthrough device designation and has FDA 510(k) clearance. According to the company, the therapy has led to dramatic improvements in people’s symptoms of severe depression in a clinical setting.

“We are thrilled to be the first site in the nation to offer the breakthrough, FDA-cleared Saint neuromodulation system for individuals suffering from depression, and I am very optimistic that this new approach will change people’s lives,” said Dr. Laura Dunn, chair of the Department of Psychiatry and director of the Psychiatric Research Institute at the University of Arkansas for Medical Sciences. “The innovative Saint protocol pro…

[Image courtesy of Magnus Medical]Magnus Medical announced today that it treated the first patients in the open-label optimization clinical trial for its Saint technology.

The OLO trial evaluates the effectiveness of Saint technology for the treatment of major depressive disorder (MDD). The platform delivers individualized, rapid-acting, non-invasive neurostimulation. Saint treats adults who fail to achieve satisfactory improvement from prior antidepressant medications in the current episode.

FDA cleared Saint for treating MDD in September 2022.

Saint combines advanced imaging technologies and personalized targeting and novel stimulation patterns. It uses structural and functional MRI to inform a proprietary algorithm. The algorithm identifies the optimal anatomic target for focused neurostimulation in people with MDD.

“We are very pleased to announce the start of the OLO clinical trial with Saint therapy for people with MDD who are ineffectively tre…

[Image from Magnus Medical]Magnus Medical announced today that it received FDA 510(k) clearance for its Saint neuromodulation system.

Burlingame, California-based Magnus designed Saint for the treatment of major depressive disorder (MDD). It treats adults who fail to achieve satisfactory improvement from prior antidepressant medications in the current episode.

The individualized, rapid-acting, non-invasive neurostimulation platform demonstrated the potential to be a reproducible, rapid and highly effective treatment for severe, refractory depression in a broader clinical setting. It received FDA breakthrough device designation in October 2021.

Saint combines advanced imaging technologies and personalized targeting and novel stimulation patterns. It uses structural and functional MRI to inform a proprietary algorithm. The algorithm identifies the optimal anatomic target for focused neurostimulation in people with MDD.

Results of a trial published in t…

Magnus Medical announced today that it received FDA breakthrough device designation for its neurostimulation technology and raised $25 million.

Burlingame, California-based Magnus designed its individualized, rapid-acting, non-invasive neurostimulation platform to treat major depressive disorder (MDD) for people who have not improved sufficiently from antidepressant medication or other treatments.

Magnus based its system on SAINT technology, which was licensed exclusively to the company from Stanford University for commercialization, according to a news release.

An article published online by the American Journal of Psychiatry included results from an investigational randomized controlled trial evaluating SAINT that demonstrated the potential to be a reproducible, rapid and highly effective treatment for severe, refractory depression in a broader clinical setting.

According to Magnus Medical Co-Founder & CSO Dr. Brandon Bentzley, the study sho…